Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-27

Study Completion Date

2021-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the clinical study is to determine the safety, reactogenicity and immunogenicity parameters of the EpiVacCorona vaccine in volunteers aged 18-60 years.

The research tasks are to:

* evaluate the safety of the EpiVacCorona vaccine when administered twice intramuscularly;
* evaluate the reactogenicity of the EpiVacCorona vaccine when administered twice intramuscularly;
* identify the development of adverse reactions to vaccine administration;
* study the humoral and cellular immune responses following two doses of the EpiVacCorona vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19

NCT04780035

COVID-19

COMPLETED PHASE3

Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above

NCT05021016

Covid19

COMPLETED PHASE3

Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older

NCT05726084

COVID-19 Coronavirus Infections Respiratory Tract Infections +1 more

UNKNOWN PHASE2/PHASE3

Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.

NCT05156723

COVID-19 Immunologic Factors Coronavirus Infections +1 more

COMPLETED PHASE1/PHASE2

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

NCT04894227

COVID-19

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The first phase of the clinical trial is an open trial. The study will enroll 14 men and women aged 18 to 30 years, inclusive, who meet the inclusion criteria and have no exclusion criteria, whose data will be used for subsequent analysis of safety and immunogenicity.

The second phase of the clinical trial is a simple, blind, placebo-controlled, randomized, parallel-group study. The study will enroll 86 men and women aged 18 to 60 years, inclusive, who meet the inclusion criteria and have no exclusion criteria whose, the data will be used for subsequent analysis of safety and immunogenicity.

If volunteers drop out of the study, they will not be replaced.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Simple, blind, placebo-controlled, randomized study involving healthy volunteers

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Masking in Phase 2

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

"EpiVacCorona" (An Open Study)

Group 1: 14 volunteers who will be vaccinated with the EpiVacCorona vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml

Group Type EXPERIMENTAL

EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)

Intervention Type BIOLOGICAL

EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.

"EpiVacCorona" (A Simple, Blind, Randomized Study)

Group 2: Administration of the EpiVacCorona vaccine, intramuscularly, twice, 21 days spaced apart, at a dose of 0.5 ml (43 volunteers)

Group Type EXPERIMENTAL

EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)

Intervention Type BIOLOGICAL

EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.

"Placebo" (A Simple, Blind, Randomized Study)

Group 3: Тhe use of placebo (sodium chloride, solvent for the preparation of dosage forms for injection 0.9%) intramuscularly twice space 21 days apart at a dose of 0.5 ml (43 volunteers)

Group Type PLACEBO_COMPARATOR

Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)

Intervention Type OTHER

The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)

EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.

Intervention Type BIOLOGICAL

Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)

The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

23. Women in the premenopausal period (the last menstruation ≤ 1 year prior to the signing of informed consent) who are not surgically sterile and women who have reproductive potential, but do not use acceptable birth controls or do not plan to use them throughout the study and do not agree to a urine test for pregnancy during the participation in the study.
24. Positive test for HIV, viral hepatitis B and C, lues venerea.
25. Other comorbidities that the researcher believes may interfere with the evaluation of the study's objectives.

And:

1. The researcher's decision to exclude the volunteer for the benefit of the volunteer.
3. The decision of the researcher or the Customer to exclude the volunteer from the study due to a clinically significant deviation from the protocol/violation of the protocol.
4. Any undesirable phenomenon requiring the appointment of drugs not authorized by the protocol of this study.
5. Refusal of a volunteer to continue to participate in the study or his/her indiscipline.
6. Volunteer's desire to complete the study early for any reason.
7. Volunteer's failure to show up for a scheduled visit without the researcher's warning or loss of communication with the volunteer.

Exclusion Criteria

1. Contacts with COVID-19 patients for 14 days prior to the start of the clinical trial.
2. Hypersensitivity to any component of the product, allergy to the components of the vaccine.
3. The history of allergic reactions to any vaccination in the past.
4. Serious post-vaccination reactions/complications associated with any vaccination in the past.
5. Pregnancy and breastfeeding.
6. Military personnel on conscription.
7. Persons detained in pre-trial detention facilities and those serving sentences in prison.
8. Children under the age of 18.
9. Symptoms of any disease at the time of inclusion in the study or if it has passed less than 4 weeks since recovery.
10. The history of any acute respiratory disease within less than 3 months prior to inclusion in the study.
11. The history of acute infectious or non-communicable diseases, exacerbation of chronic diseases within less than 4 weeks before the start of the study.
12. The history of tuberculosis (pulmonary and extrapulmonary), cancer, autoimmune diseases, skin diseases (pemphigus, psoriasis, eczema, atopic dermatitis).
13. Long-term use (more than 14 days) of immunosuppressive drug, systemic glucocorticosteroids or immunomodulatory drugs within 6 months prior to the study.
14. Vaccination with any vaccine within one month prior to vaccination.
15. Taking immunoglobulin drugs or blood products within last 3 months prior to the study.
16. The history of treatment with human immunoglobulin drugs within, less than 6 months since such treatment.
17. Donation (450 ml of blood or plasma and more) within less than 2 months prior to the study.
18. Acute or chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine system, as well as diseases of the gastrointestinal tract, liver, kidneys, surgery on the gastrointestinal tract (except appendectomy).
19. The history of participation in other clinical trials within less than 3 months prior to the start of this study.
20. Individuals with alcohol, drug dependence or drug addiction. Taking more than 10 units of alcohol per week (1 unit of alcohol is equivalent to 1/2 litre of beer, 200 ml of wine or 50 ml of alcohol) or anamnestic information about alcoholism, drug addiction, and substance misuse. Individuals with positive results of urine examination for drugs and/or with alcohol findings in the exhaled air during the visits.
21. Mental illness and neurasthenia.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes